Amino.Desk

N-acetyl Semax amidate

Updated Nov 17, 2026 · Clinical review: pending

N-acetyl Semax amidate is Semax with a chemical cap on each end, added so the peptide resists breakdown. It is sold as a stronger, longer-lasting Semax. The modified version has not been studied in people.

What it is

Semax is a seven-amino-acid peptide registered in Russia. This version adds an acetyl group at one end and an amide at the other. Both changes block the enzymes that normally break the peptide down within minutes.

What the evidence shows

Whatever the Semax studies show, they are studies of unmodified Semax. A clinical education source puts the problem plainly: claiming the molecule behaves differently while claiming the original evidence applies unchanged is inconsistent.

One guide reports that the modified version has no clinical studies, and that a laboratory study found acetylation removed one of Semax's protective mechanisms. Semax's own human evidence is small, mostly Russian studies that have not been independently repeated.

Legal status

Reported dosing

We do not publish a protocol for this compound.

No dose has been established for this modified version. Dosing on seller pages is borrowed from the parent peptide or invented.

Safety

Common questions

Is N-acetyl Semax amidate stronger than Semax?

It is designed to last longer. Nobody has tested whether that makes it work better in people.

Has N-acetyl Semax amidate been studied in humans?

No. The human studies are of unmodified Semax.

Is it covered by the 2026 compounding policy?

The policy names Semax. We have found nothing that extends it to the modified version.

Ask an AI about this page

Opens the assistant with a question about this page already typed in. You can edit it before sending.

Ask ChatGPTAsk ClaudeAsk Perplexity

These are outside services. Amino Desk does not control or review their answers, and an AI summary is not medical advice. Check anything important against the sources below.

Sources

Free field guide

Forty peptides and GLP-1s: who can legally get what, how strong the evidence is, and what to check before you pay. Plus one short email a week on what changed.

Leave at any time. We do not sell or share your address. Privacy